Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Core Viewpoint - Salarius Pharmaceuticals, Inc. has announced a public offering expected to raise approximately $7 million before expenses, which will be used to advance clinical development and for general corporate purposes [1][5]. Offering Details - The offering consists of 2,514,335 shares of common stock and pre-funded warrants for 2,152,331 shares, along with Series A and Series B Warrants for a total of 4,666,666 shares each [2]. - The public offering price is set at $1.50 per share and accompanying warrants, and $1.4999 per pre-funded warrant and accompanying warrants [2]. - Ladenburg Thalmann & Co. Inc. is the sole book-running manager for the offering [3]. Closing Conditions - The closing of the offering is anticipated on or about November 12, 2025, contingent upon the completion of a proposed business combination with Decoy Therapeutics Inc. [4]. - An option has been granted to the underwriter to purchase an additional 699,999 shares and/or warrants within 45 days at the public offering prices [4]. Use of Proceeds - The net proceeds from the offering will be allocated to advancing clinical development programs, paying off Decoy's promissory notes, and for general corporate purposes including working capital and capital expenditures [5]. Warrant Details - Pre-funded warrants have an exercise price of $0.0001 and are immediately exercisable, while Series A and Series B Warrants have an exercise price of $1.50, with different exercise periods [6]. Company Background - Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, with its lead candidate seclidemstat currently in a Phase 1/2 clinical study [10]. - Decoy Therapeutics, Inc. is a preclinical-stage biotechnology company utilizing machine learning and AI for drug development, focusing on respiratory viruses and GI cancers [11].